IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

ADVANCES IN CRPS RESEARCH : FROM PATHOPHYSIOLOGY TO PHARMACOTHERAPHY AND PROSPECTIVE TREATMENTS

[1]Mr.Kartik Kore , [2]Ms.Akanksha Dyavarshetti ,[3]Ms.Supraja Gujar

[1]Co-author, [2]Co-author, [3]Co-author

[123]Amepurva Fouram's Nirant Institute of Pharmacy,Solapur,Maharashtra,India

1. Abstract

The signs and symptoms of complex specific discomfort a spectrum of both motor and autonomic abnormalities in extremely varied combinations, together with pain that occurs either on its own or is brought about by stimuli and is out of proportion to the triggering situation, are the hallmarks of a group of disorders collectively referred to as CRPS. Patients who experience trauma, limb fractures, or limb surgery may develop CRPS. Pathophysiology andaetiology are just two of the several unresolved inquiries concerning CRPS.Thus, among these factors, we concentrated on the genetic framework for CRPS. Type l occurrences takes place in the absence of an established injury. Where there is a known associated with nerve injury, it is type ll. Severalcentral and peripheral symptoms are involved, which may change over time among individuals. Autonomic changes, immunological and inflammatory responses, neurochemical changes, psychological, and hereditary variables are additional issues for consideration. In this qualitative evaluation, we complied the mostrecent research on the genetic correlation of CRPS and examined the functions of the genes found in each study as well as the study's inefficiencies. As indicated by the syndrome's name, the physiological alterations brought about by the triggering injury are intricate. Ancontinuous circle of suffering, loneliness, and sadness is produced by the pain and incapacity brought on by CRPS, which frequently results in psychiatric co-morbidities. Moreover a few studies have proposed distinct aetiologies for certain CRPS symptoms. A broad spectrum of possible mechanisms have been shown in various investigations. Peripheral nociceptors of C-fibres have been demonstrated to be activated by neuropathic inflammation, which is a crucial factor in chronic regional pain syndrome. In accordance with whether the CRPS is acute or chronic. Therefore, more research is needed that includes a large numberof case groups and a precise, uniform classification of CRPS. However treating the chronicversion of CRPS effectively can frequently be difficult.

2. Key words

Continuous discomfort , Neurobiology, pathological processes, Prospective treatment, HLA antigens, Pharmacotherapy.

3. Introduction

CRPS, is a neuropathic pain condition characterized by persistent pain that is disproportionate for the extent of tissue injury and lasts longer than is often suspected for tissue regeneration.[1] A severe harm can cause the syndrome of complex regional pain (CRPS), a chronic neurologic syndrome with a prevalence of 5.4–26.2 per 100,000 person years.[2] Allodynia, hyperalgesia, abnormalities with the sudomotor and cardiovascular systems, and trophic fluctuations are various of those diseases.A particular dermatome or myotome isn't followed by pain, which is localized.This debilitating ailment frequently follows a fracture, surgery or trauma.[3,4] However reports of certain spontaneous occurrences have also been made. [5] It is estimated that disorders of the central and peripheral systems of nerves cause CRPS.[6] A feminine compaired to manly proportion of 3:1 is associated with a lesser frequency of it in those geriatric 61-70.[6,7,8] The most common signs include perverse nail and hair development patterns, localized sweating, temperature and color changes in the skin, and patient discomfort.[10,11] Patients who have experienced high-energy trauma, are female, and have sustained an upper extremity injurymay be more susceptible to this condition according to epidemiologic trends.[2]

Patients withCRPS have been shown to develop pathogenic autoantibodies that attack the ANS. [12] To fully understand the genesis and role of these antibodies in CRPS , more research is required.[12] It can be divided into two types: type II (CPRS; evidence with nerve damage inthe affected limbs) and type I (CRPS; proof without nerve damage) [13] the clinical appearance and course of the disease can vary in CRPS. Despite receiving treatment, manypatients nevertheless have significantly reduced quality of life and dismal outlook.[14-17] In addition to having adverse effect on everyday activities, sleep and functions. CRPS also hasa major psychological and emotional impact on the patient. [18-20] Early diagnosis and therapy are crucial to inhibiting the disease's progression and enhancing the patient's quality of life. The objective of this review is to present a current an overview of studies on the pathophysiology, epidemiology, and medications which is more available for CRPS.

4. Diagnostic Standard

As the diagnostic standard is about equal to the number of names.[21] The exclusion of motor and trophic aspects, which are commonly associated with CRPS, from the IASP criteria was one element that contributed to its lack of specificity. At least one symptom must be present during evulation in two or more of the four previously described Classifications- perceptual, cardiomotor, reversible motor /edema, and /or motor; moreover ,there must not be a more appropriate diagnosis to explain the patient's indications and manifestations, according to the Budapest Criteria.

Additionally, the patient must continue to experience discomfort that is disproportionate to any trigger. Allodynia, hyperesthesia, and/or their presence are instances of sensory complaints. Vasomotor symptoms include changes in skin colour, asymmetry in skin colour, and the presence or reporting of temperature asymmetry. The symptoms of sudo-motor/edema include edoema reports, existence of edoema, changes in sweating patterns, and asymmetry in sweating.

Motor/trophic symptoms include reduced flexibility of movement, abnormal motor function (Definiency, shiver, instability), and/or trophic abnormalities (hair, nail, skin).[22] In the lack of an objective diagnostic test, it is necessary to apply criteria to define a patient sample as well as validate diagnostic standards, in the absencean impartial diagnostic examination, this validation process entails circular reasoning and after that, to differentiate it from other diagnostic categories.[23]

5.Epidemiology

The greatest population-based research on CRPS conducted in the US to date was releasedin 2016. Among the 33,406,123 research participants, 22,533 patients (or 0.07%) were released after receiving, a CRPS diagnosis according to thorough from 2007 to 2011 in the patient sample database.[24] Future more, an independent examination among the same data base revealed notable rise in medical care use and expense in CRPS sufferers both at the time ofdiagnosis and a year earlier.[25] Its crucial to keep in mind that CRPS is not just a condition that affects growns up, even though there is definitely not enough information to support this diagnosis and treatment for children's health issues. Karri et al.'s 2021 comprehensive review addresses neuromodulator, a recognised treatment for CRPS in children adult modalities for patients in paediatric settings.[26] Pain relief and enhanced functionality across all domains are the major goals of CRPS treatment for the paediatric population to ensure that to enhance the patients standard of living of the patient. Cognitive behavioural therapy intervention is mixed

with intense physical therapy as part of therapy.[27] Numerous Epidemiological studies have been carriedout, and it appears that the presentation varies depending on the locale.[28] However, Kim andcolleagues' epidemiologic investigation revealed some significant variations.Utilizing information from the National Health Insurance Service of Korea, researchers examined point information from the over 74000 patients, making this survey significantly larger than the previous two.[29]The Kim and Colleagues survey is likely to be more reflective if it emphasises objective symptoms and diagnostic testing. Ott and Maihofner's and Sandroni and colleagues surveys are probably more representation if they place greater emphasis on clinical criteria.[28-30]

6.Pathophysiology

It's doubtful that a single direct medium causing CRPS development will be set up. Some individuals now accept that an intricate medium associated with the central and further assistance whim-whams systems is the cause of CRPS.[18] There's substantiation for each process intertwined in the birth of the condition, indeed though there's a lack of experimental data regarding how these pathways may have worked together to induce CRPS.[31] The distinctive characteristics of CRPS include an aberrant tissue response to damage, elevated peripheraland central nervous system sensitivity, and concomitant deregulation and inflammatory alterations.[15] Patients with unilateral CRPS symptoms also have abnormalities in their sympathetic nervous system and there may be somatomotor system involvement. Differentsubtypes of CRPS may exist depending on the relative contribution of the pathogenic mechanism involved.[32,33] In the meantime, the literature has described a number of pathophysiologic pathways for CRPS. The evidence from science does not suggest a singleprimary mechanism. As a result, it appears that there are multiple factors at play. Autonomic alterations, immunological, central, peripheral, and inflammatory sensitivities have all beenexamined in CRPS.[15]

6.1Peripheral Nervous System

It's likely that a stressful or driving event alters the supplemental shivers system in a certain way, which sets off the development of CRPS. Pro-inflammatory intermediates similar as prostaglandin E2 and tumour necrosis factor- inception(TNF- commencement) are released precociously and induce nociceptive sensation. [34] Additionally, a relationship between the sympathetic and peripheral noiceptive neural circuits may eventually give rise to the distinct symptomatology of CRPS.[35] Due to this sensitization, the depolarization threshold locally decreases, which probably contributes to the patients hyperalgesia.[34] Following the initial injury the release of pro-inflammatory markers causes the peripheral nervous system to become sensitized. Peripheral nerve fibres susceptibility to catecholamines has also been linked to CRPS. [15] Patients with CRPS were investigated with transmission electron microscopy. Large somatomotor AA nerve fibres were found to have significantly degenerated, whereas a nerve fibres remained intact, according to the researchers. In any case it seems likely that chronic modifications to the peripheral nervoussystem are significant. [36]

6.2Inflammation

Two features of CRPS affect neuropeptide signaling and an inflaming immune response.[37] Inflammation is a typical adverse effect after surgery, a stroke, or tissue trauma.However, individuals with chronic regenerative pain syndrome (CRPS) experience prolonged and heightened immune system activation.[17] Most of these symptoms normalizewith RPS indicating a shift in pathogenesis.[38] The evolution of CRPS has been linked to HLA class 1 antigens, and researchers have also examined the roles autoimmunity and antigens play in the body's reactions to injury.[39] Patients with CRPS have been reported to develop pathogenic autoantibodies directed against the ANS. [12] Confirmed indigenous pain pattern is allowed to be largely caused by neuropathic inflammation. When supplemental C- fiber nociceptors are actuated, pain signals are transferred efferently to the affected towel and afferently to the rearward ganglia.[40] To fully understand the source and purpose of these autoantibodies on CRPS, more research is required.[12] This backward transmission causes the synthesis of two anti-inflammatory neuropeptides: the substance P and a peptide linked to the calcitonin gene (CGRP).[41] Two anti-inflammatory neuropeptides develop as an outcome of this backward transmission: substance P and a peptide involved to the calcitonin gene (CGRP). Hyperalgesia and allodynia were brought by keratinocyte proliferation and changes in CNS inflammation.[42]

6.3Autonomic Nervous system

Clinical symptoms of syndrome of complex regional pain (CRPS), including changing skin color, increased heart rate, reduced heart rate variability, not sufficient output of the heart, and excessive sweat, usually occur by autonomic nervous system dysfunctions. Due to nociceptive nerve fibers in CRPS patients have more sympathetic receptors, there is an increase in sympathetic-afferent coupling.[43] The sympathetic-afferent coupling found in CRPS is characterized by an increase of accepting receptors that are on nociceptive nerve fibers. Thus, sympathetic hyperactivity is the cause of improved pain & sympathetically sensitivity of nociceptive nerves.[17] Orthostatic dysfunction and heart rate canresult from widespread autonomic deregulationin CRPS. [44] Vasodilation results from a decrease in catecholamine release in heated CRPS, whereas vasodilation occurs in cold CRPS.[15] Meanwhile, considering experimental models indicate a close link between the nervous system that regulates autonomic function and the pain-producing Aδ & C whim-whams filaments, there could potentially be a physical remodelling.[34] This is anticipated to ultimately lead to an increase in supplemental catecholamine perceptivity.[45] Excessive vasoconstriction and hyperhidrosis then ensue, whichcauses the clammy, cold extremities that are observed throughout the chronic phase of illness.[45] There is no question that the pathophysiology of CRPS has a significant underlying adrenergic component. Also, cases reporting hyperalgesia in response to phenylephrine injections had specially advanced expression situations of cutaneous alpha1- adrenergic receptors.[46] More recent study indicates that the sympathetic nerve is implicated in the initial pain pathways when sympathetic filaments mature into the DRG followed spinal whim-whams ligation.[47]

6.4Autoimmunity

Advanced than normal situations of autoantibodies in CRPS patients serum, skin, and apkins cases are among the earlier exploration findings that give scientific evidence of autoimmunity in CRPS.[48] Autoantibodies that honor a exterior antigen on autonomic neurons that's reliant on isolation have been set up in the serum of cases suffering from CRPS l and ll.[49,50] It is thought that autoantibodies sensitize nociceptors, causing pain in people with CRPS. Newly, rodent models were used to study the impact of investing blood IgG from CRPS cases into mice that had lacerations on their posterior paws.[51] Immunoglobulin, G(IgG) autoantibodies that exterior- bind to nervous neurons have been set up in

the tube of CRPS cases, raising the possibility that autoimmunity could have a part in the configuration of CRPS.[50,52] The results of a tiny pilot research that treated CRPS patients with intravenous immunoglobulin would corroborate this. Compared to a placebo, the therapy confirmed a significant reduction in pain sensation.[53] It provides more evidence in favour of an autoimmune etiology.[53] Each structure within the pain matrix plays a vital role in the autonomic nervous system (ANS), contributing to both cognitive and emotional processes.This suggests that there is an automatic and functional connection between the ANS and the pain matrix.[54]

6.5Sympathetic nervous system

The sympathetic nerve system may be associated in the genesis of habitual pain growth and were as shown by clinical autonomic dysfunction signs such as edema, skin color and changes in temperature, and hyperhidrosis.It was once believed that an overactive sympathetic nervous system caused RSD.[55- 59] A feature of CRPS's chronic phase clinical history is vasoconstriction, which makes the affected area blue and miserable. Sympathetic nervous system hyperactivity, which is allowed to be a sign of the complaint's advancement and a cause of the pain, suggests this process.[60] Experimental investigation suggests that an believable base for sympathetically convinced pain could be the conformation of adrenergic receptors on nociceptive filaments following towel damage and whim- whams trauma.[18,61] This is in line with the adult human sweat gland intervention's co-expression of acetylcholine and adrenergic markers.[62]

6.6CRPS and Malignancy

Numerous investigations have shown that type l many various cancer types associated to complex regional pain syndrome, and it could potentially cause unbearable pain in critically ill individuals. When CRPS type I manifests without a known cause and there is high chance ofcancer, occult cancer should be recognized and taken into consideration Numerous studies have demonstrated the potential link between gynaecologic cancers, such as vulvar and cervical tumours, and CRPS-I in lower extremities. On the other hand,

upper extremity CRPS-I is frequently caused by ovarian tumours. It took only around six months from the time that CRPS-I symptoms started to manifest to the actual diagnosis of cancer for most of these patients who had CRPS-l in their upper body. The diagnostic criteria for CRPS-I may also be broadened to include four types of clinical manifestations and a minimum of two positive criteria in order to differentiate the illness in cancer patients.[63,64]

7.CNS

Supplemental whim-whams stimulation has been to enhance the effectiveness of synaptic nociceptive activation in the rearward cornucopia following injury.[65] This has also been shown in animal models, where a decrease in allodynia is caused by intrathecal antagonist of substance P.[66] The central nervous system is subject to structural changes throughout time, just like the supplemental nervous system. For instance, there have been reports that CRPS patient’s limbs comprise a less representation than unaffected limbs in the somatosensory cortex.[67]

As the pain worsens, it may cause central nervous system symptoms such as motor disorders, inattention, and forgetfulness. Additionally, some people experience muscle dystonia and decreased range of movements involving the wrists, toes, and fingers. The good clinical outcome of intrathecal baclofen administration suggests the possible involvem ent of a central gamma-amino butyric acid system.[68]

7.1Autonomic dysregulation

As previously mentioned, connections between nociceptive and adrenergic neurons is thought to occur in CRPS, resulting in greater pain following sympathetic stimulation.[34-36] Additionally, autonomic dysfunction can explain distinct aspects of CRPS symptomatology. For instance, changes in the levels of catecholamine in the blood can account for the transition from warm to cold extremities.[65-69] Studies have demonstrated, which may eventually cause peripheral catecholamine sensitivity to rise and excessive vasodilation, oedema, and limb temperature increases.The cold, clammy extremities that are observed during the illness chronic stage are caused by the development of vasoconstrictionand hyperhidrosis.[45]

7.2Immunologic

Immunologic factors are probably essential to the development of CRPS.More specifically, a rise substance P and other neuropeptides CGRP causesthe production pertaining to pro-inflammatory mediators, some of which increase peripheral sensitization to painful stimuli. These mediators include nerve growth factor (NGF),TNF- a, interleukin (IL)-1b, and IL -6.[70-72] Further, the synthesis of neuropeptides (substances P and CGRP) and cytokines increases tissue permeability and vasodilation which manifests clinically as warmer temperatures and oedema.[73] Though studies have demonstrated an initial rise in many between inflammatory cytokines and cells , this tendency not at all always maintained, and mast cells might not be the rise of long-term illness.[42] The researchers postulated that in CRPS, there is a disruption of the typical neural - mast cell relationship, which results in extended inflammation and delayed tissue healing.[75] Additionally,there is evidence linking autoimmunization to the onset of CRPS. Intensifying inflammation and
aggiavating symtoms.[49] Indeed ,Investigative research has revealed that anti-autonomic immunoglobulin G antibodies are present in as many as 70% of this pantients serum. Its yet unclear how significant this results are.[70]

7.3Genetic influence

Research is presently being done to determine how genetics affect the development of CRPS. The researchers discovered 31 families with several impacted membersand came to the conclusion that there is a familial connection to a higher frequency of multiple limb involvement and an earlier beginning. They were unable to identify a particular inheritance pattern, though.[76] In spite of this, research efforts to pinpoint particular genotypes linked to CRPS appear promising. It was discovered that the HLA subtypes B62 and DQ8 were considerably connected to the onset of a fixed dystonia disease.[77] Numerous genes are related to immunology, cell motility, and signal transduction.[78] Investigating certain microRNA (miRNA) signatures is an additional intriguing field of genetic research. It has been demonstrated that these brief non-coding RNA fragments directly affect gene expression.[70] If further investigation is needed to determine whether the development of CRPS has a hereditary component, more research is required to establish this.[79]

7.4Psychological Strain

Empirical data suggests that some mental states may increase a patient's vulnerability to the onset of a disease. When comparing patients with CRPS to controls, there is a numerically noteworthy rise in the prevalence of PTSD.[80] There may be a propensity in many of those people as PTSD starred before CRPS symptoms appeared. It seems increasingly certain that psychological stress influences how a disease progresses. It has been shown that patients experience a worsened course of their illness when they experience increased sense of unease and perception impairment, dread associated to pain. [81] Catastrophizing, overly detrimental psychological reactions to unpleasant inaddition, stimuli be a noteworthy factor in the creation of chronic pain syndrome.[82] Proinflammatory cytokine it has been demonstrated that activity rise as a result to painful incentives and individuals' propensity has been linkede to an increase in pain scores in the future.[83] Alterations in grey matter volume are also associated with catastrophizing in young patients, which may have an impact on the development of pain and chronic motor function.[84]

8.Genetic Factors/ determinants

Current research is investigating towards the genetic influence on the establishment of CRPS. Among a group regarding Dutch individuals with the illness, a 2009 study investigated familial inheritance.[76] There isn't enough evidence to support the hypothesis that genetic factors influence the diagnosis, despite some family-based study suggesting a genetic susceptibility for developing CRPS.[85] Likewise, there has been significant substantiation linking the HLA- B62 and HLA- DQ8 allele, two HLA(mortal leukocyte anti atoms, to a possible base for CRPS.[86] These genes are related to this disorder and are part of the major histocompatibility complex. After identifying 31 familieswith multiple afflicted members, the researchers came to the conclusion that a familial connection is linked to a higher incidence and an earlier beginning of multiple limb involvement.[76] In spite of this, research efforts aimed at identifying particular genotypes linked to CRPS appeared fascinating. The development of a disease known as fixed dystonia was found to be substantially associated with the HLA categories B62 and DQ8.[77]

A new study investigated the relationship between exosomes enriched in miR-939 were ingested, human cells changed in terms of gene expression.[87] Investigating certain microRNA (miRNA) signatures is an additional intriguing field of genetic research. It has been demonstrated that these brief non-coding RNA fragments directly affect gene expression.[70] According to a 2011 study, patients with CRPS has considerably higher levels of 18 different miRNA signatures when compared to controls, which may point to a novel therapeutic target.[70,88] Concerning a disagreeing 2016 study, the results suggested no relevant variation in the quantification of over 200,000 unique different polymorphisms of one nucleotide between control and CRPS cases.[79] More investigation is required to ascertain whether CRPS development is linked to a hereditary component.

9.Treatment

Successful Treatment of CRPS is a chronic illness that presents challenges.[89] A combination of neuropathic pain medications, medical and professional therapy, psychological counselling, anti- inflammatories, and interventional procedures are used to treat CRPS primarily symptomatically.[81,83] The efficacy of numerous medications used to treat CRPS is derived fromtheir ability to effectively cure neuropathic pain.[90] Given the severe nature of CRPS, peoplemay recover on their own, but given the urgency of aggressive therapy, it is best to start treatment right once to avoid unfavourable consequences.[91]

9.1Physical/ therapy Occupational/psychological

A multimodal strategy involving medical, professional and mental therapy is advised recommendations for treating CRPS.[83,92] Key early elements of treatment for CRPS sufferers include physical and occupational therapy, which assist them get over their fear of pain and kine- sophorism.Numerous the healing approaches, including apply massage, electroshock, needeles, feedback from within, symmetrical fortification , reverse strain,and mild range of motion, has been examined. Despite the fact that the evidence was of relatively low quality,an analysis of 18 RCTs by Cochrane , reflection treatment and graded motor imagery were most beneficial physiotherapy therapies for rehabilitation, considerably lowering suffering and improving life.[4,93] Recently, a modified graded comparative effectivenessstudy was conducted to access the effectiveness of women who have had a distal radius fracture treated with cast immobilisation and are at risk of developing CRPS should participate in a motor imaging programme.[94] Physical therapy has a number of suggested mechanisms of action, but be single, comprehensive theory has emerged. Hand treatment and exercise release endorphins and release other central and peripheral analgesic processes, which enhance range of motion, function, and decrease disability.[4,95]

9.2Neuropathic pain medication

There hasn't been much research done on Neuropathic painkillers for CRPS.Neuropathic pain killers are used inorder to treat CRPS with the fact that they are effective in treatingother neuropathic disorders.[90]Thirty-four patients were monitored for six weeks after being randomly allocated should be administered gabapentin.Both medications worked well to lessen the intensity of the pain and enhance sleep; no statistically significant distinction could be found between them.[96] There haven't been any more tricyclic antidepressants investigated in RCTswith CRPS patients. Carbamazepine is an anticonvulsant medication which inhibits sodium channels, was investigated I a short research including CRPS patients who received 600 mgday^1 for eight days. The trail demonstrated pain decreases.[97]

9.3Anti-inflammatory medications

It has not been adjusted shown the at NSAIDS work well in lessening discomfort in certain neuropathic disorders.[98] Non-steroidal anti-inflammatory drugs (NSAIDS) and oral corticosteroids had been employed to treat CRPS because one theory holds that inflammation has a part in the aetiology of the condition. The results of three trials comparing coronary steriods orally to substitute supported the 2013 Cochrane review's conclusion because oral steroids don’t considerably lessen discomfort in patients with CRPS.[99] Oral prednisone seems to be more effective as opposed to piroxicam increasing composite CRPS levels when having a stroke survivors, according to another study.[100] Numerous small scale research has been done on the application of NSAIDS within CRPS.[101,102] A more recent trial indicated that modest oral dosage of prednisone therapy for two months was secure and beneficial for treatingCRPS following a stroke.[103]

9.4Intervention procedures

9.4.1. Sympathetic block

It is thought that CRPS has sympathetic as its underlying pathophysiologic mechanism.[44] Typically, sympathetic nerve blocks (SNBs) are used by interventional pain doctors to helptheir CRPS patients feel less pain. Patients with upper limb CRPS will undergo a stellate block of ganglion,whereas those with termite will undergo a lumbar sympathetic block.[104] The potency of this kind regarding CRPS therapy could not be definitively concluded by a more current cochrane analysis carried out in 2016

due to a lack of data.[104]

9.4.2. Spinal Column Activation

Spinal column activation , or SCA, is the process of delivering electrical arousal to the lumbar column of the vertebral column. The electrodes are attached to a pulse generator or other power source and are percutaneously placed into the epidural area.[105] Adrenergic inhibition, vasodilation, reversal of cortisol maladaptive neuroplasticity alterations, and suppression of spinal cord nociceptive neural conduction are some of the mechanism of action of SCS that have been hypothesised. The effectiveness of SCS within CRPS was examinedduring a thorough analysis conducted in 2017. The authors came to the conclusion that there's substantial evidence in favor of SCA usuage in CRPS patients improved pain scores.[104]

9.4.3. Dorsal root ganglion

A relatively recent and evolving technique is activation of the dorsal root ganglion (DRG)

which includes applying electrical excitation to the DRG.Peripheral sensory neurons'the DRG has cell bodies. DRG stimulation in CRPS patients showed potential, according to a 2015 case report.[106] The results of the ACCURATE trail, which included

152 CRPS patients, were published in 2017. The study compared SCS and DRG stimulation. DRG stimulation was shown to be more successful than conventional SCS in this multicentre randomised experiment in lowering suffering and enhancing individuals quality of life who suffer from CRPS.
[107]

10. Prevention of CRPS: Vitamin C

The estimated number of patients who develop CRPS after suffering from distal radial fractures is 10%.[108] Cases with fractures involved in a future, double-eyeless trial that had been published in the Journal in 1999 of their wrists entered either a placebo or a 500 mg the antioxidant vitamin C capsule as a precautionary antioxidant for a period of 50 days. It is suggested that vitamin C operate less danger therapeutic by obstructing antioxidant-mediated pro-inflammatory channels. [109] The preventative reducing agent a placebo was compared with 200, 500, and 1500 mg of vitamin C administered during 50 days following a wrist fracture in a double-blind, dose-responsive study conducted in 2007 on prospective customers.[110] Patients were randomized receive a placebo or 500 mg of vitamin C for 50 days. There was not a significant shift in the study's results of CRPS, bone healing, or functional outcomes.[111] Vitamin C was given at a dosage of 1000 mg, and the groups receiving the intervention and control were divided based on time. Taken as a preventative, the authors of the study suggested vitamin C. The study's authors suggested taking vitamin C as a preventative measure. [112] As a result of the uneven results and typically poor quality of the data, it is uncertain if intake of vitamin C generally has a substantial impact on lowering the occurrence of CRPS. However, due to the small beneficial findings, vitamin C may still be a viable intervention that doctors use for individuals with distal distal fractures or during foot or ankle surgery. Some guidelines suggest it with a moderate their degree of strength.[113]

11. In Summary

Though uncommon in the general population, complicated regional pain syndrome can occur to people had limb surgery following a crush injury. Both peripherally and centrally involved CRPS processes may be apparent, and they may vary over time betweenpatients and even within patients. Humans with a 3:1 female to male ratio between the agesof 61-70 years old are more likely to have CRPS. A complicated pathophysiological mechanism including both inflammatory and neurological pathways causes the emergence of regional pain syndrome. Concerning the overall result of RSD/

CRPS, very little accurate data is accessible. There are multiple reasons for this. First off, the majority of patient cohorts thathave been published currently have been manipulated at tertiary pain clinics or other facilities that specialize in treating CRPS; as such, they probably reflect the extreme and persistent end of the range. As a result, combined therapy involving both medication and surgical procedures may be necessary for the treatment of CRPS in the future. Researchinto these strategies is also required.

References

1.Stanton-Hicks MD. CRPS: what's in a name? Taxonomy, epidemiology, neurologic, immune and autoimmune considerations. Reg Anesth Pain Med. 2019 Mar;44(3):376-387.
2.Peterson PB, Mikkelsen KL, Lauritzen JB, Krogsgaard MR, Risk factors for post- treatment complex regional pain syndrome (CRPS): an analysis of 647 cases of CRPS from the Danish Patient Compensation Association. Pain Pract 2018; 18: 341-9 .
3.Goebel A. Complex regional pain syndrome in adults. Rheumatology (Oxford). 2011 Oct;50(10):1739-50.
4.Smart KM, Wand BM, O'Connell NE. Physiotherapy for pain and disability in adults withcomplex regional pain syndrome (CRPS) types I and II. Cochrane Database Syst Rev. 2016 Feb 24;2(2):CD010853.
5.de Rooij AM, Perez RS, Huygen FJ, van Eijs F, van Kleef M, Bauer MC, van Hilten JJ, Marinus J. Spontaneous onset of complex regional pain syndrome. Eur J Pain. 2010 May;14(5):510-3.
6.S. Bruehl, R.N. Harden, B.S. Galer, S. Saltz, M. Bertram, M. Backonja, M. Stanton- Hicks External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria Pain, 81 (1-2) (1999), pp. 147-154.
7.M. de Mos , A. G. J. de Bruijn, F. J. P. M. Huygen , J. P. Dieleman, C. B. H. Stricker, and M. C. J.
M. Sturkenboom, "The incidence of complex regional pain syndrome: a population- based study," Pain, vol. 129 no. 1 , pp. 12-20, 2007.
8.M. de Mos, F. J. P. M. Huygen, J. P. Dieleman, J. S. H. A. Koopman, C. B. H. Stricker, and M. C. J.
M. Sturkenboom, "mMedical history and the onset of complex regional pain syndrome (CRPS)," Pain, vol. 139 no. 2 pp. 458-466, 2008.
9.H. S. An, K. B. Hawthorne, and W. Thomas Jackson, " The Journal of Hand Surgery, vol. 13, no. 13, pp. 458-460, 1988.
10. T. Eberle, B. Doganci, H. H. Kramer et al., " Warm and Cold complex regional pain syndromes: differences beyond skin temperature?" Neurology, vol. 72 , no. 6, pp. 505-512, 2009.
11. F. Birklein, B. Riedl, N. Sieweke, M. Weber, and B. Neundorfer, " Neurological findings in complex regional pain syndrome- analysis of 145 cases," Acta NeurologicaScandinavica, vol. 101, no. 4, pp. 262- 269, 2000.
12. D. Kohr, M. Tschernatsch, K. Schmitz et al., "Autoantibodies in complex regional painsyndrome bind to a differentiation dependent neuronal surface autoantigen," Pain, vol.143, no. 3, pp. 246- 251, 2009.
13. Marinus J, Moseley GL, Birklein F, Baron R, Maihöfner C, Kingery WS, van Hilten JJ. Clinical features and pathophysiology of complex regional pain syndrome. LancetNeurol 2011; 10:637-648.
14. Eldufani J, Elahmer N, Blaise G. A Medical mystery of complex regional pain syndrome. Heliyon. 2020;6(2):e03329. https://doi.org/10.1016/j.heliyon.2020.e03329
15. Shim H, Rose J, Halle S, Shekane p. Complex regional pain syndrome: narrative review for the practicing clinician .Br.JAnaesth 2019;123(2):e424-33. https://doi.org/10.1016/j.bja.2019.03.030.
16. Urits I, Shen AH, Jones MR, Viswanath O, Kaye AD. Complex regional painsyndrome, current concepts and treatment options. Cure Pain Headache Rep. 2018. https://doi.org/10.1007/s11916-018- 0667-7.

17. Misidou C, Papagoras C. Complex regional pain syndrome: an update. Mediterr J Rheumatol. 2019;30(1):16-25. https://doi.org/10.31138/mjr.30.1.16.
18. Bruehl S. An update on the pathophysiology of complex regional pain syndrome. Anesthesiology. 2010 Sep;113(3):713-25.
19. Galer BS, Henderson J, Perander J, Jensen MP. Course of symptoms and quality of lifemeasurement in Complex Regional Pain Syndrome: a pilot survey. J Pain Symptom Manage. 2000 Oct;20(4):286- 92.
20. Lohnberg JA, Altmaier EM. A review of psychosocial factors in complex regional painsyndrome. J Clin Psychol Med Settings. 2013 Jun;20(2):247-54.
21. van de Beek WJ, Schwartzman RJ, van Nes SI, Delhaas EM, van Hilten JJ. Diagnostic criteria used in studies of reflex sympathetic dystrophy. Neurology 2002;58:522–6 22.Harden RN, Bruehl S, Perez RSGM, et al. Validation of proposed diagnostic criteria (the ‘‘Budapest Cri-teria’’) for complex regional pain syndrome. Pain. 2010;150(2):268–74. https://doi.org/10.1016/j.pain. 2010.04.030.
23. Harden RN, Bruehl S, Galer BS, Saltz S, Bertram M, Backonja M, et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive? Pain 1999;83:211– 9.
24. Elsharydah A, Loo NH, Minhajuddin A, Kandil ES.Complex regional pain syndrome type 1 predic- tors—epidemiological perspective from a national database analysis. J Clin Anesth. 2017. https://doi.org/10.1016/j.jclinane.2017.03.027
25. Elsamadicy AA, Yang S, Sergesketter AR, et al. Prevalence and cost analysis of complex regional pain syndrome (CRPS): a role for neuromodulation. Neuromodulation. 2018;21(5):423–30. https://doi.org/10.1111/ner.12691
26. Karri J, Palmer JS, Charnay A, et al. Utility of elec-trical neuromodulation for treating chronic pain syndromes in the pediatric setting: a systematic review. Neuromodulation. 2021. https://doi.org/10.1111/ner.13365.
27. Weissmann R, Uziel Y. Pediatric complex regionalpain syndrome: a review. Pediatr Rheumatol. 2016. https://doi.org/10.1186/s12969-016-0090-8.
28. Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain 2003; 103: 199-207
29. Kim H, Lee CH, Kim SH, Kim YD. Epidemiology of complex regional pain syndromein Korea: an electronic population health data study. PLoS One 2018; 13, e01981476.
30. Ott S, Maihofner C. Signs and symptoms in 1,043 patients with complex regional pain syndrome. J Pain 2018; 19:599-611
31. C. Chang, P. McDonnell, M.E. Gershwin Complex regional pain syndrome–False hopes and miscommunications Autoimmun. Rev. (2019)
32. W. Janig and R. Baron, " Complex regional pain syndrome is a disease of the central nervous system," Clinical Autonaomic Research, vol. 12, no. 3, pp. 150-164, 2002.
33. S. Bruehl, R.N. Harden, B. S. Galer, S. Saltz, M. Backonja, and M. Stanton-Hicks, "Complex Regional Pain Syndrome: are there distinct subtypes and sequential stages of the syndrome?" Pain, vol.95, no. 1-2, pp. 119-124, 2002.
34. R.J. Schwartzman, G.M. Alexander, J. Grothusen Pathophysiology of complex regionalpain syndrome Expert Rev Neurother, 6 (2006), pp. 669-681
35. Janig W, Boron R. Complex regional pain syndrome: mystery explained? Lancet Neurol2003; 2: 687- 97.

36. Yvon, A. Faroni, A.J. Reid, V.C. LeesSelective fiber degeneration in the peripheral nerveof a patient with severe complex regional pain syndromeFront Neurosci, 12 (2018), p. 207
37. Li WW, Guo TZ, Shi X, et al. Neuropeptide regulation of adaptive immunity in the tibiafracture model of complex regional pain syndrome. J Neuroinflamm. 2018;15(1):105.https://doi.org/10.1186/s12974-018-1145-1.
38. L. F. Knudsen, A. J. Terkelsen, P. D. Drummond, and F. Birklein, "Complex regional pain syndrome: a focus on the autonomic nervous system," Clinical Autonaomic Research, vol. 29, no.4, pp. 457- 467, 2019.
39. W. J. T. Van de Beek, B. Roep, A. R. van der Slik, M. Giphart, and B. J. van Hilten, "Susceptibility loci for complex regional pain syndrome," Pain, vol.103, no.1, pp. 93-97,2003.
40. T. Schlereth, J. O. Dittmar, B. Seewald, and F. Birklein, " Peripheral amplification of sweating- a role for calcitonin gene-related peptide," The Journal of physiology, vol. 576,no. 3, pp. 823-832, 2006.
41. Littlejohn G. Neurogenic neuroinflammation in fibromyalgia and complex regional painsyndrome. Nat Rev Rheumatol. 2015;11:639-48. https://doi.org/10.1038/nrrheum.2015.100.
42. Birklein F, Drummond PD, Li W, et al. Activation of cutaneous immune responses incomplex regional pain syndrome. J Pain. 2014;15(5):485-95. https://doi.org/10.1016/j.jpain.2014.01.490.
43. Kundsen LF, Terkelsen AJ, Drummond PD, Birklein F. Complex regional pain syndrome:a focus on the autonomic nervous system. Clin Auton Res.2019;29(4):457-67. https://doi.org/10.1007/s10286- 019-00612-0.
44. Terkelsen AJ, Mølgaard H, Hansen J, Finnerup NB, Krøner K, Jensen TS. Heart rate variability in complex regional pain syndrome during rest and mental and orthostatic stress. Anesthesiology. 2012 Jan;116(1):133-46.
45. E.L. Goh, S. Chidambaram, D. Ma Complex regional pain syndrome: a recent update Burns Trauma, 5 (2017), p. 2
46. Drummond PD, Morellini N, Finch PM, Birklein F, Kundsen LF. Complex regionalpain syndrome. Pain. 2018;159(11):2296- 305.https://doi.org/10.1097/j.pain.0000000000001335.
47. Chen S-S, Zhang J-M. Progress in sympathetically mediated pathological pain. J AnesthPerioper Med. 2015;2(4):216-25. https://doi.org/10.24015/japm.2015.0029.
48. Tajerian M, Clark JD. New concepts in complex regional pain syndrome. Hand Clin. 2016;32(1):41-9. https://doi.org/10.1016/j.hcl.2015.08.003.
49. Blaes F, Schmitz K, Tschernatsch M, Kaps M, Krasenbrink I, Hempelmann G, et al. Autoimmune etiology of complex regional pain syndrome (M Sudeck). Neurology 2004;63:1734-6.
50. Kohr D, Tschernatsch M, Schmitz K, Singh P, Kaps M, Schäfer KH, et al. Autoantibodiesin complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. Pain 2009;143:246-51.
51. Cuhadar U, Gentry C, Vastani N, et al. Autoantibodies produce pain in complex regional pain syndrome by sensitizing nociceptors. Pain. 2019;160(12):2855-65 . https://doi.org/10.1097/j.pain.0000000000001662.

52. E. Dubuis, V. Thompson, M.I. Leite, F. Blaes, C. Maihofner, D. Greensmith, et al. Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptors Pain, 155 (11) (2014), pp. 2408-2417
53. Goebel, A. Baranowski, K. Maurer, A. Ghiai, C. McCabe, G. Ambler Intravenous immunoglobulin treatment of the complex regional pain syndrome: a randomized trial Ann. Intern. Med., 152 (3) (2010), pp. 152-158
54. M. Leone. Proietti Cecchini, E. Mea, V. Tullo, M. Curone, and G. Bussone, "Neuroimaging and pain: a window on the autonomic nervous system," Neurological Sciences, vol. 27, no. S2, pp. S134-137, 2006.
55. Kurvers HA, Jacbos MJ, Beuk RJ, Van den Wildenberg FA, Kitslaar PJ, Slaaf DW, et al. Reflex sympathetic dystrophy: evolution in microcirculatory disturbances in time. Pain 1995;60:333-40.
56. Kurvers HA, Hofstra L, Jacbos MJ, Daemen MA, van den Wildenberg FA, Kitslaar PJ, et al. Reflex sympathetic dystrophy: does sympathetic dysfunction originate from peripheral neuropathy? Surgery 1996;119: 388-96.
57. Ide J, Yamaga M, Kitamura T, Takagi K. Quantitative evaluation of sympathetic nervoussystem dysfunction in patients with reflex sympathetic dystrophy. J Hand Surg Br 1997;22:102-6.
58. Kurvers HA, Jacbos MJ, Beuk RJ, van de Wildenberg FA, Kitslaar PJ, Slaaf DW et al. Reflex sympathetic dystrophy: result of autonomic denervation? Clin. Sci (Lond) 1994;87:663-9.
59. Christensen K, Henriksen O. The reflex sympathetic dystrophy syndrome. An experimental study of sympathetic reflex control of subcutaneous blood flow in thehand. Scand J Rheumatol 1983;12:263- 7.
60. L.F. Knudsen, A.J. Terkelsen, P.D. Drummond, F. Birklein Complex regional pain syndrome: a focus on the autonomic nervous system Clin. Auton. Res. (2019), pp. 1-11
61. R. Baron, J. Schattschneider, A. Binder, D. Siebrecht, G. Wasner Relation between sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional painsyndromes: a case–control study Lancet, 359 (9318) (2002), pp. 1655-1660.
62. Weihe E, Schutz B, Hartschuh W, Anlauf M, Schafer MK, Eiden LE, Coexpression of cholinergic and noradrenergic phenotypes in human and nonhuman autonomic nervous system. J Comp Neuronal 2005; 492:370-9.
63. N. Mekhail, L. Kapural Complex regional pain syndrome type I in cancer patients Curr. Rev. Pain, 4 (3) (2000), pp. 227-233
64.K.B. Guthmiller, M. Varacallo Pain, complex regional pain syndrome (ReflexSympathetic Dystrophy, RSD, CRPS) StatPearls [Internet], StatPearls Publishing (2018) 65.Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152: S2e151
66. Guo TZ, Offley SC, Boyd EA, Jacobs CR, Kingery WS. Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture ratmodel of complex regional pain syndrome type I. Pain 2004; 108: 95-107
67. Di Pietro F, McAuley JH, Parkitny L, et al. Primary somatosensory cortex function in complex regional pain syndrome: a systematic review and meta-analysis. J Pain 2013; 14: 1001-18
68. van Rijn MA, Marinus J, Putter H, van Hilten JJ. Onset and progression of dystonia in complex regional pain syndrome. Pain 2007; 130: 287-931

69. Bussa M, Mascaro A, Cuffaro L, Rinaldi S. Adult complex regional pain syndrome TypeI: a narrative review. PM R 2017; 9: 707-19
70. Birklein F, Ajit SK, Goebel A, Perez R, Sommer C. Complex regional pain syndrome - phenotypic characteristics and potential biomarkers. Nat Rev Neurol 2018; 14: 272-84
71. David Clark J, Tawfik VL, Tajerian M, Kingery WS. Autoinflammatory and autoimmunecontributions to complex regional pain syndrome. Mol Pain 2018; 14.1744806918799127
72. Kingery WS. Role of neuropeptide, cytokine, and growth factor signaling in complex regional pain syndrome. Pain Med 2010; 11: 1239-50
73. Birklein F, Schlereth T. Complex regional pain syndrome significant progress in understanding. Pain 2015;156(Suppl 1): S94-103
74. Morellini N, Finch PM, Goebel A, Drummond PD. Dermal nerve fibre and mast cell density, and proximity of mast cells to nerve fibres in the skin of patients with complex regional pain syndrome. Pain 2018; 159: 2021-9
75. Blaes F, Schmitz K, Tschernatsch M, et al. Autoimmune etiology of complex regional pain syndrome (M. Sudeck).Neurology 2004; 63: 1734-6
76. de Rooij AM, de Mos M, Sturkenboom MC, Marinus J, van den Maagdenberg AM, van Hilten JJ. Familial occurrence of complex regional pain syndrome. Eur J Pain 2009; 13:171-7
77. de Rooij AM, Florencia Gosso M, Haasnoot GW, et al. HLAB62 and HLA-DQ8 are associated with Complex Regional Pain Syndrome with fixed dystonia. Pain 2009; 145:82-5
78. Jin EH, Zhang E, Ko Y, et al. Genome-wide expression profiling of complex regional pain syndrome. PLoS One 2013; 8, e79435
79. Janicki PK, Alexander GM, Eckert J, Postula M, Schwartzman RJ. Analysis of common single nucleotide polymorphisms in complex regional pain syndrome: genome wide association study approach and pooled DNA strategy. Pain Med 2016; 17: 2344-52
80. Speck V, Schlereth T, Birklein F, Maihofner C. Increased prevalence of posttraumatic stress disorder in CRPS. Eur J Pain 2017; 21: 466-73
81. Urits I, Shen AH, Jones MR, Viswanath O, Kaye AD. Complex regional pain syndrome,current concepts and treatment options. Curr Pain Headache Rep 2018; 22: 10
82. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995; 7:524-32
83. Harden RN, Oaklander AL, Burton AW, et al. Complex regional pain syndrome: practicaldiagnostic and treatment guidelines, 4th edition. Pain Med 2013; 14: 180-229
84. Erpelding N, Simons L, Lebel A, et al. Rapid treatment induced brain changes in pediatricCRPS. Brain Struct Funct 2016; 221: 1095-111
85. A.M. De Rooij, M. de Mos, J.J. van Hilten, M.C. Sturkenboom, M.F. Gosso, A.M. van den Maagdenberg, et al.Increased risk of complex regional pain syndrome in siblings ofpatients? J. Pain, 10 (12) (2009), pp. 1250-1255.
86. T. Higashimoto, E.E. Baldwin, J.I. Gold, R.G. Boles Reflex sympathetic dystrophy: complex regional pain syndrome type I in children with mitochondrial disease and maternal inheritance Arch. Dis. Child., 93 (5) (2008), pp. 390-397.
87. D' Agnelli, Gerra MC, Bignami E, Arendt- Nielsen L. Exosomes as a new pain biomarkeropportunity. Mol Pain. 2020;16:1-9. https://doi.org/10.1177/1744806920957800.
88. I.A. Orlova, G.M. Alexander, R.A. Qureshi, et al.MicroRNA modulation in complex regional pain syndrome J Transl Med, 9 (2011), p. 195.

89. F. Birklein and V. Dimova, "Complex regional pain syndrome-up-to-date," Pain Reports,vol. 2, no. 6, p. e624, 2017.
90. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-51
91. Lee JW, Lee SK, Choy WS. Complex Regional Pain Syndrome Type 1: Diagnosis and Management. J Hand Surg Asian Pac Vol. 2018 Mar;23(1):1-10.
92. Ghai B, Dureja G. Complex regional pain syndrome: a review. J Postgrad Med 2004; 50:300-7
93. Me´ndez-Rebolledo G, Gatica-Rojas V, Torres-Cueco R, Albornoz-Verdugo M, Guzma´n-Mun˜oz E. Update on the effects of graded motor imagery and mirror therapyon complex regional pain syndrome type 1: a systematic review. J Back Musculoskelet Rehabil. 2017;30(3):441–9. https://doi.org/10.3233/BMR-150500.
94. McGee C, Skye J, Van Heest A. Graded motor imagery for women at risk for developingtype I CRPS following closed treatment of distal radius fractures: a randomized comparative effectiveness trial protocol. BMC Musculoskelet Disord. 2018. https://doi.org/10.1186/s12891-018-2115-6.
95. Nijs J, Kosek E, Van Oosterwijck J, Meeus M. Dysfunctional endogenous analgesia during exercise in patients with chronic pain: to exercise or not to exercise? Pain Physician. 2012 Jul;15(3 Suppl):ES205-13.
96. Brown S, Johnston B, Amaria K, et al. A randomized controlled trial of amitriptyline versus gabapentin for complex regional pain syndrome type I and neuropathic pain in children. Scand J Pain 2016; 13: 156-63
97. Harke H, Gretenkort P, Ladleif HU, Rahman S, Harke O. The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained- release morphine in patients pretreated withspinal cord stimulation: a double-blinded randomized study. Anesth Analg 2001; 92: 488-95
98. Rasmussen-Barr E, Held U, Grooten WJ, et al. Nonsteroidal anti-inflammatory drugs forsciatica: an updated cochrane review. Spine (Phila Pa 1976) 2017; 42: 586-94
99. O'Connell NE, Wand BM, McAuley J, Marston L, Moseley GL. Interventions for treatingpain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD009416.
100. Kalita J, Vajpayee A, Misra UK. Comparison of prednisolone with piroxicam incomplex regional pain syndrome following stroke: a randomized controlled trial. QJM. 2006 Feb;99(2):89-95.
101. Breuer AJ, Mainka T, Hansel N, Maier C, Krumova EK. Short-term treatment with parecoxib for complexregional pain syndrome: a randomized, placebo-controlled double-blind trial. Pain Physician 2014; 17:127-37
102. Eckmann MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocainein the treatment of complex regional pain syndrome of the lower extremity: a randomized, double- blinded, crossover study. Clin J Pain 2011; 27: 203-6
103. Kalita J, Misra U, Kumar A, Bhoi SK. Long-term Prednisolone in Post-stroke Complex Regional Pain Syndrome. Pain Physician. 2016 Nov-Dec;19(8):565-574.
104. O'Connell NE, Wand BM, Gibson W, Carr DB, Birklein F, Stanton TR. Local anaesthetic sympathetic blockade for complex regional pain syndrome. Cochrane Database SystO'Connell NE, Wand BM, Gibson W, Carr DB, Birklein F, Stanton TR. Local anaesthetic sympathetic blockade for complex regional pain syndrome. CochraneDatabase SystRev 2016; 7: CD004598
105. Verrills P, Sinclair C, Barnard A. A review of spinal cord stimulation systems for chronic pain. J Pain Res 2016; 9: 481-92
106. Van Buyten JP, Smet I, Liem L, Russo M, Huygen F. Stimulation of dorsal root gangliafor the management of complex regional pain syndrome: a prospective case series. PainPract 2015; 15: 208-16
107. Deer TR, Levy RM, Kramer J, Poree L, Amirdelfan K, Grigsby E, Staats P, Burton AW, Burgher AH, Obray J, Scowcroft J, Golovac S, Kapural L, Paicius R, Kim C, Pope J, Yearwood T, Samuel S, McRoberts WP, Cassim H, Netherton M, Miller N, Schaufele M, Tavel E, Davis T, Davis K, Johnson L, Mekhail N. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgiaat 3 and 12 months: a randomized comparative trial. Pain. 2017 Apr;158(4):669-681.
108. Koval K, Haidukewych GJ, Service B, Zirgibel BJ. Controversies in the management of distal radius fractures. J Am Acad Orthop Surg 2014; 22: 566-75
109. Zollinger PE, Tuinebreijer WE, Kreis RW, Breederveld RS. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. Lancet 1999; 354: 2025-8
110. Zollinger PE, Tuinebreijer WE, Breederveld RS, Kreis RW. Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study. J Bone Jt Surg Am 2007; 89: 1424-31

111. Ekrol I, Duckworth AD, Ralston SH, Court-Brown CM,McQueen MM. The influence of vitamin C on the outcomeof distal radial fractures: a double-blind,randomizedcontrolled trial. J Bone Jt Surg Am 2014; 96: 1451-9
112. Besse JL, Gadeyne S, Galand-Desme S, Lerat JL, Moyen B. Effect of vitamin C on prevention of complex regional pain syndrome type I in foot and ankle surgery. Foot Ankle Surg 2009; 15: 179-82
113. Lichtman DM, Bindra RR, Boyer MI, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: the treatment of distal radius fractures. J Bone JtSurg Am 2011; 93: 775-8